Obesity has impacts on cardiovascular disease outcomes through increased risk of coronary artery disease, heart failure (more prominent with preserved ejection fraction), cardiac arrhythmias (most significantly atrial fibrillation), sudden death, and venous thromboembolism [7]
Ther Adv Endocrinol Metab (2015) 6:10934
Already used as a drug to treat hypoglycaemia, DiMarchi began working on finding a better way to synthesise glucagon so that it could be administered more easily
In weight loss clinical trials, semaglutide helped people lose about 15 percent of their body weight on average significantly more than the currently available obesity drugs and more than enough to improve health outcomes
If you take insulin or sulfonylureas for diabetes, monitor your blood glucose closely when reducing calorie intake, as you may be at increased risk for hypoglycemia and require medication adjustments
All medications come from licensed 503A compounding pharmacies